Invention Grant
- Patent Title: Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
-
Application No.: US17012448Application Date: 2020-09-04
-
Publication No.: US12023305B2Publication Date: 2024-07-02
- Inventor: Ben Whalley , Claire Williams , Gary Stephens , Takashi Futamura
- Applicant: GW Pharma Limited
- Applicant Address: GB Salisbury
- Assignee: GW Pharma Limited
- Current Assignee: GW Pharma Limited
- Current Assignee Address: GB Cambridge
- Agency: COOLEY LLP
- Priority: GB 05364 2010.03.30 GB 00042 2011.01.04
- The original application number of the division: US14685753 2015.04.14
- Main IPC: A61K31/05
- IPC: A61K31/05 ; A61K31/19 ; A61K31/352 ; A61K31/40 ; A61K31/515 ; A61K36/185 ; A61K45/06 ; A61P25/08
Abstract:
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
Public/Granted literature
- US20210100755A1 USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY Public/Granted day:2021-04-08
Information query
